Q-omics provides the consensus-scored SUMO2P15 profile across patient tissues and cancer cell-line models. SUMO2P15 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SUMO2P15 is differentially expressed in 5, with the highest sampling consensus in UCEC. Additionally, SUMO2P15 RNA expression shows 13,631 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and UCEC as cancer lineages where SUMO2P15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUMO2P15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUMO2P15 survival associations across molecular data types. SUMO2P15 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUMO2P15 RNA expression–survival associations across cancer types. High SUMO2P15 expression shows unfavorable associations in UVM, KICH, THCA and READ, but favorable associations in LIHC and LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for SUMO2P15 RNA expression.
This table summarizes SUMO2P15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SUMO2P15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUMO2P15 shows lower tumor expression in UCEC, BRCA, READ, LUSC and LUAD. The UCEC box plot shows higher SUMO2P15 RNA expression in normal versus tumor tissue (log2 FC = −0.425, t-test p = .004).
This table shows molecular features associated with SUMO2P15 in patient tissues and cancer cell lines. In patient samples, SUMO2P15 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
